September 9th 2023
Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.
In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.
September 8th 2023
In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.
Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.
September 7th 2023
An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.
Ponatinib Stimulates â€˜Powerfulâ€™ Response in Treatment-Resistant Leukemias
Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistanceâ€”including the stubborn T315I mutationâ€”in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Prescribing TKIs for the Treatment of CML
Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.
2 Clarke Drive Cranbury, NJ 08512